



25<sup>th</sup> Annual Meeting  
of the European  
Charcot Foundation

25 Years of  
Fundamental  
Milestones in MS



30 November  
- 2 December  
2017

Grand Hotel Dino  
Baveno, Italy

## Thursday November 30, 2017

10:10 - 10:35

*Welcome Coffee*

10:35 - 11:35

Satellite Symposium EXCEMED - Excellence in Medical Education  
Today's choices for tomorrow's reality

Introduction and welcome  
Giancarlo Comi

Immunological modes of action and clinical efficacy of emerging MS treatments  
Heinz Wiendl

High efficacy treatments in the management of patients  
Klaus Schmierer

Tackling clinical decision making and conclusions  
Gavin Giovannoni

11:35 - 11:45

*Break*

11:45 - 12:45

Industry-sponsored Satellite Symposium

Merck Satellite Symposium

Cladribine Tablets in MS: providing durable efficacy and a reduced monitoring burden through a unique MoA

Welcome and objectives  
Hans-Peter Hartung

Cladribine Tablets: an innovative treatment that provides durable efficacy in MS  
Oscar Fernandez

Cladribine Tablets: Safety and tolerability profile and implication for monitoring  
Antonio Uccelli

Q&A - Panel discussion

Wrap up and Close  
Hans-Peter Hartung  
*Light Lunch*

12:45 - 13:15

13:15 - 14:15

XXV ECF Lecture  
Comi Giancarlo - Chair

History of the Foundation and what has changed in these 25 years in Multiple Sclerosis

van Eikema Hommes Otto R.

14:15 - 16:00

SESSION I: ABOUT THE CAUSES OF THE DISEASE  
Ebers George - [Chair](#)

Lecture 1: Epidemiology  
Scalfari [Antonio](#)

Lecture 2: Genetic  
[Sawcer Stephen](#)

Lecture 3: Environmental factors  
[Ascherio Alberto](#)

Lecture 4: Mucosal biopsy shows immunologic changes of the colon in patients with early MS  
Moser [Adrian Mathias](#)

*Coffee Break and Poster Viewing*

16:00 - 16:30

SESSION II: THE CHANGING LANDSCAPE OF BASIC STUDIES

Freedman Mark - Chair

16:30 - 18:00

Lecture 1: Pathology

[Brück Wolfgang](#)

[Lecture 2: From a T cell story to a complex immune mechanism](#)

[Wekerle Hartmut](#)

[Lecture 3: Pathophysiological mechanism in the various phases of the disease](#)

[Lassmann Hans](#)

[Lecture 4: Intrathecal inflammatory profile and cortical damage can stratify MS patients](#)

[Magliozzi Roberta](#)

18:00 - 18:15

*Coffee Break*

18:15 - 19:15

Industry-sponsored Satellite Symposium

Sanofi Genzyme Satellite Symposium

Evolving landscapes in MS research and clinical practice - From traditional to novel measures

Welcome and Introduction

Nicola De Stefano

Novel clinical measures to assess MS-related parameters and treatment efficacy

Ralf Linker

New insights into patient-reported outcomes in MS

Iris-Katharina Penner

Q&A

19:15 - 20:15

*Welcome Cocktail*

## **Friday December 1, 2017**

08:30 - 10:15

SESSION III: HOW THE MS FACE HAS CHANGED

Fujihara Kazuo - Chair

Lecture 1: Diagnostic criteria a never ending story

[Edan Gilles](#)

Lecture 2: Classification of disease courses

[Cohen Jeffrey](#)

Lecture 3: At the border of MS (NMOSD, ADEM, anti MOG)

[Palace Jacqueline](#)

Lecture 4: Distinguishing MOG antibody disease from childhood MS

Hacohen Yael

10:15 - 11:15

*Coffee Break and Poster Viewing*

11:15 - 13:00

SESSION IV: HOW TO MONITOR DISEASE EVOLUTION AND TREATMENT

Miller Ariel - Chair

Lecture 1: Role of brain MRI

Fazekas Franz

Lecture 2: Role of spinal cord MRI

[Filippi Massimo](#)

Lecture 3: Body fluids

Khalil Michael

Lecture 4: Neurophysiological biomarkers included OCT and more

Leocani Letizia

13:00 - 14:00

*Lunch*

14:00 - 15:45

SESSION V: CLINICAL TRIALS AND OUTCOME MEASURES

Boyko Alexey - Chair

Lecture 1: Clinical trial designs  
Kappos Ludwig

Lecture 2: Outcome measures  
Hobart Jeremy

Lecture 3: Patient reported outcomes  
[Solari Alessandra](#)

[Lecture 4: Clinical trials in pediatric MS](#)  
[Ghezzi Angelo](#)

*Coffee Break*

15:45 - 16:15

16:15 - 18:00

SESSION VI: FROM NO TREATMENT TO A COMPLEX TREATMENT ARMAMENTARIUM  
Selmaj Krzysztof - Chair

Lecture 1: The evolution of treatment for relapsing MS  
Hartung Hans-Peter

Lecture 2: Do we really hit the phenomenon of progression with available treatment  
Montalban Xavier

Lecture 3: Efficacy and effectiveness  
Trojano Maria

Lecture 4: Risk minimization in MS treatment  
[Uitdehaag Bernard M. J.](#)

*Coffee Break*

18:00 - 18:15

18:15 - 19:15

Industry-sponsored Satellite Symposium

Celgene Satellite Symposium

The evolution of MS Treatment: S1P Modulators; reviewing ongoing clinical development programs

Welcome and Introductions  
Maria Pia Amato

Exploring the Underlying Mechanism of Disease  
Ludwig Kappos

S1P Modulators and Phase 2 & 3 Trials  
Hans-Peter Hartung

Meeting Close  
Maria Pia Amato

## **Saturday December 2, 2017**

07:15 - 07:30

*Light Breakfast*

07:30 - 08:30

Satellite Symposium MS in the 21st Century

Welcome and Introductions

Dawn Langdon

The digital healthcare revolution: A journey towards patient engagement  
Gavin Giovannoni

Debate: Patient power – do the benefits always outweigh the risks?  
Gavin Giovannoni & David Yeandle

Moderated by: Dawn Langdon

Talking the same language: Progress and challenges for joint communication in MS  
Peter Rieckmann & David Yeandle

Q&A  
Dawn Langdon

Close

Dawn Langdon

08:30 - 10:15

SESSION VII: ENHANCING RECOVERY AND SYMPTOMATIC TREATMENT

Thompson Alan - Chair

Lecture 1: Molecular mechanism to enhance recovery

[Lubetzki Catherine](#)

[Lecture 2: Where we are with physical and mental exercise](#)

[Kesselring Jürg](#)

[Lecture 3: Symptomatic treatment](#)

[Sorensen Per Soelberg](#)

Lecture 4: Regenerative approaches for demyelinating diseases

Simons Mikael

10:15 - 10:45

*Coffee Break*

10:45 - 12:00

SESSION VIII: TRANSLATING SCIENCE INTO PATIENT MANAGEMENT

Cristiano Edgardo - Chair

Lecture 1: How MS care is changed in Europe

Fernandez Oscar

Lecture 2: Dealing with increasing economic constraints

Giovannoni Gavin

Lecture 3: Multistakeholder initiative

Vermersch Patrick

Lecture 4: MS center organization

Comi Giancarlo

12:00 - 12:30

Young Investigator Awards

12:30 - 13:00

Closing Remarks

13:00 - 14:00

*Lunch*